Two cancer researchers who hold a patent on a particular pathway that might be a target for new drugs — and one of whom leads a company that is studying those potential drugs — have retracted two related papers in the Journal of Biological Chemistry (JBC).
The notices for “Kinase suppressor of Ras signals through Thr269 of c-Raf-1” and “The kinase activity of kinase suppressor of Ras1 (KSR1) is independent of bound MEK,” which share H. Rosie Xing and Memorial Sloan-Kettering’s Richard Kolesnick as authors, say the same thing:
This article has been withdrawn by the authors.
The first paper has been cited 49 times, according to Thomson Scientific’s Web of Knowledge, while the second has been cited 13.
One of the papers is cited by a U.S. patent Xing and Kolesnick hold, “Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis.” Kolesnick is chief scientific officer of Ras Therapeutics, which licensed Ras technology from Sloan-Kettering.
We also found a Corrigendum published in 2011 of a 2003 Nature Medicine paper on which Xing and Kolesnick are first and last authors, respectively:
In the version of this article initially published, there are irregularities with the tubulin loading controls in lanes 1 through 4 and with the KSR1 bands in lanes 7 and 8 of Figure 2f. The authors have repeated the experiment and have provided a new figure panel that is now published as part of the correction notices linked to the HTML version and attached to the PDF version of the article. The original figures remain in both online versions of the article. The authors have also made a correction to Supplementary Figure 6b, which has been added to the supplementary file online. H. Rosie Xing does not agree to this correction.
Kolesnick did not respond to a request for comment. Xing seems to have been at the University of Chicago most recently, but her email bounced, and the press office did not respond to us.
Hat tip: Rolf Degen